tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Zentek CEO Resigns to Lead U.S. Venture, Strategic Licensing Deal Announced

Story Highlights
Zentek CEO Resigns to Lead U.S. Venture, Strategic Licensing Deal Announced

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Zentek ( (TSE:ZEN) ) is now available.

On September 3, 2025, Zentek Ltd. announced the resignation of Greg Fenton as CEO, who will now lead Altek Advanced Materials Inc., a U.S.-based venture. This transition is part of a strategic move to accelerate the commercialization of Zentek’s technologies, including ZenGUARD™, in the U.S. market through a licensing agreement with Altek. The agreement allows Altek to manufacture and commercialize Zentek’s products in the U.S., while Zentek retains its intellectual property rights. This shift is expected to enhance Zentek’s market presence with minimal additional resources. Wendy Ford, the CFO, has been appointed as interim CEO while the company searches for a new leader.

The most recent analyst rating on (TSE:ZEN) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Zentek stock, see the TSE:ZEN Stock Forecast page.

Spark’s Take on TSE:ZEN Stock

According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.

Zentek’s overall stock score is primarily impacted by its financial performance challenges, including negative margins and cash flows. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative earnings. The absence of earnings call and corporate events data limits further insights.

To see Spark’s full report on TSE:ZEN stock, click here.

More about Zentek

Zentek Ltd. is an ISO 13485:2016 certified intellectual property technology company focused on the research, development, and commercialization of innovative products. The company aims to provide its commercial partners with a competitive edge by enhancing their products to be better, safer, and greener. Zentek’s patented ZenGUARD™ technology is known for its enhanced viral filtration efficiency, and the company holds a global exclusive license for an Aptamer-based platform developed with McMaster University for diagnostic and therapeutic markets.

Average Trading Volume: 54,867

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$135.1M

For detailed information about ZEN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1